Kynam Capital Management, LP Reduces Stake in Pharvaris in Latest 13F Filing

Kynam Capital Management, LP Reduces Stake in Pharvaris in Latest 13F Filing

Kynam Capital Management, LP has disclosed a notable reduction in its position in Pharvaris (NASDAQ: PHVS) according to its latest SEC 13F filing. The hedge fund sold 34,610 shares of the medical biology company, marking a 0.05% decrease in its holdings. This move reflects a strategic adjustment in its portfolio allocation.

Deep Dive into the Trade

As of the filing, Kynam Capital Management, LP holds a position in Pharvaris valued at $17.77 million, representing 1.19% of its total portfolio. Despite the reduction, the firm still owns approximately 0.98% of Pharvaris’ total outstanding shares. The trade comes amidst Pharvaris' involvement in the medical biology sector, a field known for its innovation and volatility, which may have influenced this decision.

Market Context

Why is Kynam Capital Management, LP Adjusting Its Position in Pharvaris?

The sell-off may suggest a rebalancing of the fund’s exposure to the medical biology sector or a response to recent market developments affecting Pharvaris. Investors often adjust holdings to optimize returns or mitigate risks, particularly in sectors as dynamic as medical biology.

How Much of Pharvaris Does Kynam Capital Management, LP Own?

Post-adjustment, Kynam Capital Management, LP retains a 0.98% ownership stake in Pharvaris, underscoring its continued interest in the company despite the reduced position.

Portfolio Impact

Pharvaris now constitutes 1.19% of Kynam Capital Management, LP’s portfolio, reflecting its ongoing, albeit slightly diminished, importance within the fund's investment strategy. This adjustment may indicate a shift in focus or a tactical decision to redistribute capital across other opportunities.

For a detailed view of Kynam Capital Management, LP’s full real-time portfolio and historical 13F data, click here.